Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Olatunji Boladale Alese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8079-4725; OpenAlex author ID A5047220835. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 0, last author 2)
Trials
6 (principal investigator on 6)
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2016: 1 paper, 1 trial · 2017: 1 trial · 2018: 1 paper, 1 trial · 2019: 2 papers, 1 trial · 2020: 3 papers, 2 trials · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Co-author DOI 10.1016/j.canlet.2025.218233↗
  2. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  3. MetScore and classical–basal subtype intersect to define chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.09.14.751470↗
  4. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  5. Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer. Co-author DOI 10.1093/oncolo/oyaf284↗
  6. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  7. Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence. Last author DOI 10.1080/15384047.2023.2198479↗
  8. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002227↗
  9. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Last author DOI 10.18632/oncotarget.28242↗
  10. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. Co-author DOI 10.1097/mpa.0000000000001788↗
  11. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Co-author DOI 10.3389/fonc.2021.678070↗
  12. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  13. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. Co-author DOI 10.1097/mpa.0000000000001502↗
  14. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001584↗
  15. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  16. Induction Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001353↗
  17. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Co-author DOI 10.1634/theoncologist.2017-0487↗
  18. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Co-author DOI 10.1634/theoncologist.2015-0316↗

Trials 6

  1. Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Principal investigator NCT04191421↗
  2. Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer Principal investigator NCT04524702↗
  3. Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer Principal investigator NCT03819088↗
  4. TAS102 in Combination With NAL-IRI in Advanced GI Cancers Principal investigator NCT03368963↗
  5. VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Principal investigator NCT03373188↗
  6. Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Principal investigator NCT02897375↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 12 shared papers, 2016–2026 · strength 1.59
  2. Mehmet Akce · 8 shared papers, 2019–2025 · strength 0.99
  3. Gregory B. Lesinski · 4 shared papers, 2025–2026 · strength 0.95
  4. Walid Labib Shaib · 9 shared papers, 2016–2023 · strength 0.93
  5. Cameron J. Herting · 3 shared papers, 2025–2026 · strength 0.66
  6. Shishir Kumar Maithel · 6 shared papers, 2016–2026 · strength 0.64
  7. Christina Sing-Ying Wu · 5 shared papers, 2018–2023 · strength 0.54
  8. Juan Manuel Sarmiento · 4 shared papers, 2018–2026 · strength 0.49
  9. Chrystal M Paulos · 2 shared papers, 2026 · strength 0.47
  10. Emily R. Greene · 2 shared papers, 2026 · strength 0.47
  11. Natalie K. Horvat · 2 shared papers, 2026 · strength 0.47
  12. Maria Diab · 2 shared papers, 2026 · strength 0.47
  13. Jesse Stone Handler · 1 shared paper, 2026 · strength 0.29
  14. Udhayvir Singh Grewal · 1 shared paper, 2026 · strength 0.29
  15. Richard A. Moffitt · 1 shared paper, 2026 · strength 0.29
  16. Kawther Abdilleh · 1 shared paper, 2026 · strength 0.29
  17. Raymond E. Preston · 1 shared paper, 2026 · strength 0.29
  18. Sudheer Doss · 1 shared paper, 2026 · strength 0.29
  19. Nathan Bahary · 2 shared papers, 2021–2024 · strength 0.28
  20. Olumide B. Gbolahan · 1 shared paper, 2026 · strength 0.24
  21. David A. Kooby · 3 shared papers, 2016–2019 · strength 0.23
  22. Robert Donald Harvey · 1 shared paper, 2025 · strength 0.23
  23. Taofeek Kunle Owonikoko · 1 shared paper, 2025 · strength 0.23
  24. Alyssa M. Krasinskas · 1 shared paper, 2026 · strength 0.23
  25. Mihir Maheshkumar Shah · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.